logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients

Gilead Sciences, Inc. (GILD) reported data from two Phase 2 studies and a compassionate access study, wherin a regimen containing once-daily Sovaldi 400 mg was administered to treat chronic hepatitis C virus or HCV infection in patients with advanced liver disease.

The first study, named Study GS-US-334-0125, is an ongoing open-label Phase 2 trial assessing HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin or RBV was administered for 48 weeks or to a deferred treatment arm in which this regimen was started after a 24-week observation period.

Out of the 22 patients who completed 24 weeks of therapy, 95 percent achieved virologic suppression on treatment. Further, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm; and 80% of participants were treatment-experienced

Study GS-US-334-0126, was a single-arm open-label Phase 2 study in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV. The majority of patients had genotype 1-HCV infection and 88 percent were treatment-experienced. According to the company, seventy percent of patients in this study achieved SVR12.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT